• Medical Lasers
• /
• 제9권2호
• /
• pp.150-158
• /
• 2020

Background and Objectives Low-level laser therapy (LLLT) is used widely to promote hair growth in androgenetic alopecia (AGA). This study examined the clinical efficacy and safety of a home-use LLLT device with a newly designed array of light sources and software optimized for individual types of AGA. Materials and Methods The study was a randomized, double-blind, sham device-controlled trial. Forty-eight subjects (39 men and nine women) were assigned randomly in a 2:1 ratio to use either the test device (LG Pra'L HGN1, LG electronics, Korea) or sham device. The subjects used the LLLT device three times a week for 16 weeks. Phototrichogram was used to measure the hair density and hair thickness at 0, 8, and 16-weeks. Adverse events were closely monitored. Results After 16 weeks of using the device, the test group showed a significant increase in hair density and hair thickness compared to the control. In the test group, the hair density increased 6.96 counts/cm² at eight weeks and 13.67 counts/cm² at 16 weeks from the baseline. The hair thickness increased 7.21 ㎛ at eight weeks and 11.80 ㎛ at 16 weeks compared to the baseline. Conclusion The home-use LLLT device with a novel array of light sources and an individualized program according to the types of hair loss appears to be an effective and safe treatment modality for both male and female AGA patients.

• 한방안이비인후피부과학회지
• /
• 제32권3호
• /
• pp.164-185
• /
• 2019

Objectives : This study is carried out to analyze the use of Korean medical treatments on alopecia in Korean medicine clinical studies published in South Korea. Methods : Based on OASIS and KTKP with the keyword 'alopecia', published in 1996-2019.4.23., total 23 studies have been found and analyzed. We analyzed Korean medical treatment used in each cases, and investigated the tendency of use for each treatment. Results : 369 cases in 23 research papers were selected. Herbal medicine, acupuncture, pharmacopuncture, external medicine and other therapy were used as treatment for Alopecia. Herbal medicine with a cooling effect was mainly used. The acupoints mainly used were GV20, ST8, GB5, ST36, HT8, PC6, BL66. Pharmacopunctures used to treat alopecia were CF, HP, HH, BV, etc. The average duration of Korean medicine treatment was 144 days. After Korean medicine treatment, 292 cases presented improvement or complete recovery. Conclusions : According to the results, we were able to discover the current status of Korean medicine treatment of alopecia. Based on this result, further studies will be needed to establish the primary treatment direction of alopecia.

• 대한약침학회지
• /
• 제24권3호
• /
• pp.93-106
• /
• 2021

This study aimed to analyze the use of Korean medicine treatments for alopecia in among clinical studies. We identified and analyzed 22 studies from Korean databases; Oriental Medicine Advanced Searching Integrated System (OASIS), Science ON, Korean Studies Information Service System (KISS), and Research Information Sharing Service (RISS) and international database; PubMed. We analyzed the Korean medical treatment in each case and determined the tendency to use each intervention. We analyzed 1,464 patients from 22 selected studies. Herbal medicine, acupuncture, external medicine or products, pharmacopuncture, and phototherapy were used for alopecia treatment. The herbal medicines mainly used to treat alopecia were Gagam Cheongyoung-tang, Gagam Hwajung-hwan, and Yukmijihwang-tang·hwan. The acupoints primarily used were GV20, EX-HN1, GB5, KI3, PC6, ST36, GV22, and A-shi. The most commonly used pharmacopuncture therapies were Hwangryunhaedoktang (HH), Carthami Fructus (CF), Bee Venom (BV), and Hominis placenta (HP). The Korean medical treatment for alopecia improved the condition of patients. However, seven studies reported the occurrence of side effects such as pruritus, dazed, drowsiness, headache, pain, and diarrhea. This study shows the potential of Korean medicine for the treatment of alopecia. Further studies with a large sample size and long-term follow-up are warranted to establish the primary treatment guidelines and objective outcome measures for alopecia.

• 한국임상약학회지
• /
• 제25권3호
• /
• pp.171-177
• /
• 2015

Background: Androgenetic alopecia (AGA), one of alopecias, requires continuous treatment in order to prevent or stop it, and patient's compliance is very important. Currently, only two drugs (finasteride, minoxidil) have been approved for AGA by Food and Drug Administration of United States (US FDA). However, another ${\alpha}-2$ reductase inhibitor, dutasteride, is approved by Korea Ministry of Food and Drug Safety (MFDS) through a phase III trial. For treatment, pharmacotherapy of AGA usually combines topical minoxidil 7% with one of oral <${\alpha}-2$ reductase inhibitor. Objectives: We evaluated the comparative efficacy and adverse effect between topical minoxidil 7%/finasteride 1 mg and topical minoxidil 7%/dutasteride 0.5 mg pharmacotherapy for outpatients with AGA. Also we evaluated the relationship between therapeutic effect and regular hospital visit. Method: This study was performed retrospectively based on electronic medical record (EMR) data of total 98 patients (topical minoxidil 7% with dutasteride 0.5 mg ($Avodart^{(R)}$) or finasteride 1 mg ($Alopecia^{(R)}$, $Propecia^{(R)}$) with diagnosis of AGA from department of dermatology at a secondary hospital from January $1^{st}$, to May $31^{st}$, 2014. Results: The efficacy and adverse event of topical minoxidil 7%/dutasteride 0.5 mg (DUTA group) were 100% and 45.7%, and of topical minoxidil 7%/finasteride 1 mg (FINA group) were 92.1% and 33.3%, respectively. The mean onset time of responses and adverse events in the FINA group were 3.86 months and 4.43 months. Those in the DUTA group were 3.97 months and 5.06 months. Conclusion: Both FINA and DUTA group were highly effective, but the DUTA group showed higher efficacy and adverse effects than those in the FINA group. Dutasteride may be another alternative in AGA treatment.

• 한방안이비인후피부과학회지
• /
• 제9권1호
• /
• pp.166-172
• /
• 1996

The alopecia is classified to Alopecia areata, Telogen effluvium, Anagen effluvium and Androgenetic alopecia. The exact cause of alopecia is not known, but a inherent and immunologic anc psychosomatic and endocrinic factors are suspected. We analysed clinical study in 77 patients, who had visited to the Dept. of Dermatology, Hospital of Oriental Medicine, Kyung Hee University to treat alopecia from June, 1994 to March, 1995. The results were summarized as follows; 1. In the series of 77 patients, $52\%\;were\;male\;and\;48\%$ were female. The peak incidence of age group was 20 to 29 ($55\%$). 2. The peak incidence of age group at on set was 20 to 29 ($49\%$). 3. The most frequent feature was insomnia ($25\%$). Frequent appeared signs and symptoms in descending order were head itching, head scale, fatigue and dizziness. 4. The personal history of patient were seborrheic dermatitis ($17\%$), atopic dermatitis, disorder of thyroid gland and acne in descending order. 5. The patients with family history occupied $25\%$. 6. Shineung Yangjin Dan was most used in treatments as $36\%$.

• The Korean Journal of Physiology and Pharmacology
• /
• 제7권2호
• /
• pp.91-96
• /
• 2003

In Korean folk medicine, several herbs, Glycyrrhizae Radix, Persicae Semen, Salviae Radix, Angelicae Gigantis Radix, Zanthoxyli Fructus, Ginseng Radix Alba, Cnidii Rhizoma, and Carthami Flos, are known to enhance blood circulation and have wound healing or anti-inflammatory effects. These pharmacological actions prompted us to investigate whether these herbs might stimulate hair growth. Thus, using a mixture of their extracts called SPELA 707, we investigated their effects and found that SPELA 707 possessed significant hair cycle converting activity from the telogen phase to the anagen phase in C3H mice. Furthermore, we found that SPELA 707 enhanced the hair density in subjects with hair loss and also promoted the conversion of hair into the anagen phase in subjects with androgenetic alopecia. In addition, hair growth promotion effect of SPELA 707 occurred through inhibition of steroid $5{\alpha}$-reductase activity, which is known to block hair growth. Taken together, these results suggest that SPELA 707 has a potential to be used for the treatment of hair loss.

• 대한의생명과학회지
• /
• 제10권1호
• /
• pp.49-54
• /
• 2004

The hair growth effect of the oriental medicine extract which is composed of Polygoni multiflori Radix, Angelica gigantis Radix and Lycii Fructus was studied biochemically and histologically. The study was conducted dividelly into three groups, control, propecia and oriental medicine extract and three groups were compared each other in skin androgen, testosterone (T) and dihydrotestosterone (DHT), content biochemically and the number of hair follicular unit and hair follicle histologically. The oriental medicine extract and propecia decreased skin DHT conetent and increased skin total (T+DHT) content compared with control. In transverse sections of skin specimens the oriental medicine extract and propecia increased total counts of follicular units and follicles compared with control. On the basis of the result, the oriental medicine extract has same hair growth effect as propecia and it is suggested that the oriental medicne extract is capable of a therapeutic agent of alopecia.

• BMB Reports
• /
• 제46권9호
• /
• pp.460-464
• /
• 2013

The progression of androgenetic alopecia is closely related to androgen-inducible transforming growth factor (TGF)-${\beta}1$ secretion by hair follicle dermal papilla cells (DPCs) in bald scalp. Physiological levels of androgen exposure were reported to increase reactive oxygen species (ROS) generation. In this study, rat vibrissae dermal papilla cells (DP-6) transfected with androgen receptor showed increased ROS production following androgen treatment. We confirmed that TGF-${\beta}1$ secretion is increased by androgen treatment in DP-6, whereas androgen-inducible TGF-${\beta}1$ was significantly suppressed by the ROSscavenger, N-acetyl cysteine. Therefore, we suggest that induction of TGF-${\beta}1$ by androgen is mediated by ROS in hair follicle DPCs.

• Biomolecules & Therapeutics
• /
• 제19권2호
• /
• pp.231-236
• /
• 2011

The aim of this study was to investigate the effect of charge carrier lipid on the skin penetration, retention, and hair growth of topically applied finasteride-containing liposomes. Finasteride-containing liposomes were prepared by traditional thin film hydration method using Phospholipon$^{(R)}$ 85 G and cholesterol with or without charge carrier lipid (1,2 dimyristoyl-sn-glycero-3-phosphate or 1,2-dioleoyl-trimethylammonium-propane for anionic and cationic charge, respectively). Freshly prepared finasteride-containing liposome suspension was applied on the hairless mouse skin, and skin penetration and retention were measured using Keshary-Chien diffusion cell. Non-liposomal formulation (ethanol 10% solution containing 0.5 mg/ml of FNS) was also used as a control. The amount of finasteride in the diffusion cell and mouse skin was measured by HPLC. The hair growth was evaluated using depilated male C57BL/6N mice. Mean particle size of all finasteride-containing liposomes was less than a micron, and polydispersity index revealed size homogeneity. Skin penetration and retention studies showed that significantly less amount of finasteride was penetrated when applied as anionic liposome while more amount of the drug was retained. Specifically, in liposome prepared with 10% anionic charge carrier lipid, penetration was 12.99 ${\mu}g/cm^2$ while retention was 79.23 ${\mu}g/cm^2$ after 24 h of application. In hair growth study, finasteride-containing anionic liposomes showed moderate efficacy, but the efficacy was not found when applied as cationic liposomes. In conclusion, topical application of finasteride using anionic liposome formulation appears to be useful option for the treatment of androgenetic alopecia to avoid systemic side effects of the drug.

• Journal of Microbiology and Biotechnology
• /
• 제33권11호
• /
• pp.1467-1474
• /
• 2023

Due to the continuous increase in patients with androgenetic alopecia (AGA) and psychological disorders such as depression and anxiety, the demand for hair loss treatment and effective hair growth materials has increased. Terminalia bellirica (Gaertn.) Roxb. (TBE) reportedly exerts anti-inflammatory, hepatoprotective, and antidiabetic effects, among others, but its effects on testosterone (TS)-inhibited hair growth remains unclear. In this study, we evaluated the effects of TBE on TS-induced hair growth regression in human follicle dermal papilla cells (HFDPCs) and C57BL/6 mice. Oral administration of TBE increased TS-induced hair growth retardation. Interestingly, effects were greater when compared with finasteride, a commercial hair loss treatment product. Histological analyses revealed that oral TBE administration increased hair follicles in the dorsal skin of C57BL/6 mice. Additionally, western blotting and immunofluorescence showed that oral TBE administration recovered the TS-induced inhibition of cyclin D1, proliferating cell nuclear antigen (PCNA), and Ki67 expression in vivo. Using in vitro proliferation assays, TBE promoted HFDPC growth, which was suppressed by TS treatment. Thus, TBE may be a promising nutraceutical for hair health as it promoted hair growth in AGA-like in vitro and in vivo models.